What is it about?
There have been concerns among cardiologists that aspirin could increase the risk of hospitalization and death related to heart failure for patients with heart failure who take one of the first-line therapies: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Our findings showed aspirin does not increase heart failure events in heart failure patients. Earlier heart failure studies, smaller than our study, raised concern about a negative effect of aspirin with heart failure medications, due to a potential biochemical interaction.
Featured Image
Why is it important?
Up to 40 percent of Americans take aspirin, and in heart failure patients, this number may be even higher. Our finding allayed concerns regarding the safety of aspirin for heart failure patients. Knowledge that aspirin is safe could have implications extending beyond the world of heart failure since ACE inhibitors are also used as a front-line therapy for hypertension and diabetes,
Perspectives
Although the idea was from Prof Teerlink, I took the major role in the writing of this article. It was intellectually fun and also privileged to work with star researchers like WARCEF Investigators.
Dr Tetz Cheng-Che Lee
Columbia University
Read the Original
This page is a summary of: Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients, JACC Heart Failure, August 2017, Elsevier,
DOI: 10.1016/j.jchf.2017.04.011.
You can read the full text:
Contributors
The following have contributed to this page
